CCTG LY.12

**Time:** Saturday, December 9, 2017: 5:30- 7:30 PM  
**Location:** Georgia World Congress Center, Bldg A, Lvl 1, Hall A2  
**Type:** Oral and Poster Abstracts  
**Session:** 731. Clinical Autologous Transplantation: Results: Poster I  
**Presenter:** Shen Li  
**Abstract:** Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial (#2015)  
**Authors:** Shen Li, Annette E Hay, Michael Crump, Peter Anglin, Tara Baetz, Ralph Meyer, Armand Keating, Sue Robinson, Matthew Seftel, Caterina Stelitano, Marina S Djurfeldt, Lois E. Shepherd, Bingshu E. Chen, Sarit Assouline  
**Link:** https://ash.confex.com/ash/2017/webprogram/Paper101048.html

---

CCTG LY.12

**Time:** Monday, December 11, 2017: 7:30 AM  
**Location:** Georgia World Congress Center, Bldg A, Lvl 1, Hall A2  
**Type:** Oral and Poster Abstracts  
**Session:** 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Immune-Based Therapeutic Approaches  
**Presenter:** Sattva S. Neelapu  
**Abstract:** A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkin lymphoma (NHL) (#579)  
**Link:** https://ash.confex.com/ash/2017/webprogram/Paper99962.html
CCTG IND.216

**Time:** Monday, December 11, 2017: 6:00-8:00 PM  
**Location:** Georgia World Congress Center, Bldg A, Lvl 1, Hall A2  
**Type:** Oral and Poster Abstracts  
**Session:** 642. CLL: Therapy, excluding Transplantation: Poster III  
**Presenter:** Sarit Assouline  
**Abstract:** *A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216 (#4319)*  
**Authors:** Sarit Assouline, Lilian Amrein, Versha Banerji, Stephen Caplan, Carolyn Jane Owen, Wanda Hasegawa, Sue Robinson, Sudeep Shavikumar, Anca Prica, Anthea Peters, Linda Hagerman, Laura Rodriguez, Tanya Skamene, Lawrence Panasci, Bingshu E. Chen, Annette E. Hay  
**Link:** [https://ash.confex.com/ash/2017/webprogram/Paper102031.html](https://ash.confex.com/ash/2017/webprogram/Paper102031.html)

CCTG LY.12

**Time:** Monday, December 11, 2017: 6:00-8:00 PM  
**Location:** Georgia World Congress Center, Bldg A, Lvl 1, Hall A2  
**Type:** Oral and Poster Abstracts  
**Session:** 902 - Health Services Research—Malignant Conditions: Poster III  
**Presenter:** Anca Prica  
**Abstract:** *Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial (#4673)*  
**Authors:** Anca Prica, Annette E Hay, Michael Crump, Nicole Mittman, Lois E. Shepherd, Ralph Meyer, Kevin Imrie, Nancy A. Risebrough, Marina S Djurfeldt, Bingshu E. Chen, Matthew Cheung  
**Link:** [https://ash.confex.com/ash/2017/webprogram/Paper104689.html](https://ash.confex.com/ash/2017/webprogram/Paper104689.html)

CCTG HD.6

**Time:** Monday, December 11, 2017: 6:00-8:00 PM  
**Location:** Georgia World Congress Center, Bldg A, Lvl 1, Hall A2  
**Type:** Oral and Poster Abstracts  
**Session:** 624 - Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III  
**Presenter:** Laura N Rodriguez-Romo  
**Abstract:** *Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial (#4081)*  
**Authors:** Laura N Rodriguez-Romo, Ralph Meyer, Joseph L Pater, Jonathan Sussman, Ziwei Zhang, Lui Hongbo, Jane N. Winter, Te Vuong, Walter Blahey, Liam Mulroy, Lois E. Shepherd, Maria S djurfeldt, Bingshu E. Chen, Annette E Hay  
**Link:** [https://ash.confex.com/ash/2017/webprogram/Paper101449.html](https://ash.confex.com/ash/2017/webprogram/Paper101449.html)